Lamotrigin ratiopharm Dreifitafla 100 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

lamotrigin ratiopharm dreifitafla 100 mg

ratiopharm gmbh* - lamotriginum inn - dreifitafla - 100 mg

Lamotrigin ratiopharm Dreifitafla 200 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

lamotrigin ratiopharm dreifitafla 200 mg

ratiopharm gmbh* - lamotriginum inn - dreifitafla - 200 mg

Lamotrigin ratiopharm Dreifitafla 25 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

lamotrigin ratiopharm dreifitafla 25 mg

ratiopharm gmbh* - lamotriginum inn - dreifitafla - 25 mg

Metadon Abcur (Metadon Novum Abcur) Tafla 10 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

metadon abcur (metadon novum abcur) tafla 10 mg

abcur ab* - methadonum hýdróklóríð - tafla - 10 mg

Metadon Abcur (Metadon Novum Abcur) Tafla 20 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

metadon abcur (metadon novum abcur) tafla 20 mg

abcur ab* - methadonum hýdróklóríð - tafla - 20 mg

Metadon Abcur (Metadon Novum Abcur) Tafla 5 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

metadon abcur (metadon novum abcur) tafla 5 mg

abcur ab* - methadonum hýdróklóríð - tafla - 5 mg

Metadon 2care4 Tafla 10 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

metadon 2care4 tafla 10 mg

2care4 generics aps - methadonum hýdróklóríð - tafla - 10 mg

Metadon 2care4 Tafla 20 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

metadon 2care4 tafla 20 mg

2care4 generics aps - methadonum hýdróklóríð - tafla - 20 mg

Metadon 2care4 Tafla 5 mg 冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

metadon 2care4 tafla 5 mg

2care4 generics aps - methadonum hýdróklóríð - tafla - 5 mg

Orserdu 欧盟 - 冰岛文 - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.